BridgeMD
A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer.
EU CTIS ID: 2023-509360-24-00
What this study is testing
To compare disease-free survival (DFS) of nivolumab versus placebo in subjects with resected esophageal cancer (EC), or gastro-esophageal junction (GEJ) cancer
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- subjects diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction
- subjects completed pre-operative chemoradiotherapy followed by surgery
- subjects diagnosed with residual pathologic disease after being surgically rendered free of disease with negative margins following complete resection
You likely can't join if
- subjects diagnosed with cervical esophageal carcinoma
- subjects diagnosed with Stage IV resectable disease
- subjects who did not receive concurrent chemoradiotherapy prior to surgery
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
- Singapore
- Israel
- Brazil
- New Zealand
- Australia
- Hong Kong
- Argentina
- United States
- Russian Federation
- Mexico
- China
- Canada
- Switzerland
- Peru
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom; Singapore; Israel; Brazil; New Zealand; Australia and 9 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.